Anti Tumor Vaccine

The vaccine triggers mainly the cellular antitumoral immune responses which enable a complete destruction of different malignant and benign tumors. The vaccine possesses a vast and strong antitumoral properties due to a unique combination of telomerase antigen imitators together with more than 40 other tumor specific antigen imitators in its composition. The antigens, which are imitated by the drug, are present in cells of the most common malignant (see the list here) and benign tumors containing fibrotic and glandular tissues. When the drug is introduced into an organism, a numerous clones of antitumoral lymphocytes are formed. In those cases when thus formed antitumor immunity could achieve a complete destruction of the tumors, relapses do not occur, due to the formation of the immunological memory.
The chances of the complete destruction of a tumor depend on:1) Number of tumor cells (size of a tumor) and their mitotic activities; 2) Type of tumor- histological structures, antigen structures, the number of HLA-A class molecules on tumor cells;3) Initial state of the immune system.
In the treatment of the malignant tumors it is most effective as an antimetastatic drug, when used in combination with surgical resection of a primary tumor which, depending on the stage of the cancers, results in to a complete destruction of tumor in 30-90% of cases. RESAN vaccine when used in the complex therapy of inoperable malignant tumor (T3-T4) can give a considerable therapeutic effect. The drug does not render any toxic effect in normal cells of an organism, has no mutagenic and teratogenic effect and does not contain any cells and tissues of tumors. The main components of the vaccine are glycoproteins which imitate particular fragments of tumor antigens.
Latin name of the drug is RESAN. The antitumoral activities of the drug were researched and proved during 1992 - 2008 years. Today, the irony in the cancer world is that in spite of the great need of such drugs, they are practically absent in the medical pharmaceutical markets.